Recent Developments Boosted TScan (TCRX) Stock Up

TScan Therapeutics, Inc. (NASDAQ: TCRX) experienced a notable ascent of 10.46% on Tuesday, culminating in a closing value of $6.76. This surge in TScan’s stock value was precipitated by the disclosure of a significant corporate development.

TScan (TCRX) has officially communicated its intention to convene a virtual Key Opinion Leader (KOL) event scheduled for Monday, December 11, at 8:00 a.m. ET. During this event, TCRX will elucidate key insights derived from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Following the scripted remarks, the floor will be open for a dynamic question and answer session.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

In addition to these corporate updates, TScan has welcomed Dr. Justin McCue as its Chief Technology Officer. Dr. McCue brings to TScan an extensive background, spanning more than two decades, in the realms of biologics and cell therapy manufacturing. His expertise encompasses process/analytical development, technical operations, clinical development, and the commercialization of T cell therapy products.

Previously associated with Avectas, a pioneering cell engineering technology company, Dr. McCue held the position of Chief Technology Officer, overseeing technology development and scientific strategy. His academic qualifications include a bachelor’s degree in chemical engineering from the University of California, Berkeley, and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Furthermore, TScan has been honored as one of the Top Places to Work in Massachusetts as per the 16th annual employee-based survey project conducted by The Boston Globe. This prestigious recognition, featured online at Globe.com/TopPlaces and in the Globe Magazine on Sunday, December 3, 2023, underscores TScan’s commitment to being an exemplary workplace. The survey, gauging employee sentiments on various facets such as company direction, execution, connection, management, work, pay and benefits, and engagement, categorizes employers into size-specific groups.

Remarkably, TScan has clinched this accolade for the second consecutive year, underscoring its standing as a diligent, inclusive, and employee-centric organization. This achievement serves as a testament to the sustained excellence and dedication exhibited by the company.

Most Popular